舍曲林联合小剂量奎硫平在抑郁症患者焦虑失眠症状中的临床疗效

Sertraline in Combination with low -dose Quetiapine in Patients with Depression Anxiety and Insomnia Symptoms of Clinical Efficacy

目的：分析低剂量喹硫平联合舍曲林在抑郁症患者焦虑失眠中的临床疗效，为临床诊疗提供参考。方法：将我院收治的符合ICD-10抑郁发作或复发性抑郁症诊断标准的160例患者作为观察对象，随机分为舍曲林联合喹硫平组和单用舍曲林组，每组80例。比较2组患者治疗1周、2周、4周、8周的汉密尔顿抑郁量表（HAMD）及汉密尔顿焦虑量表（HAMA）及HAMD睡眠因子情况。结果：2组患者治疗前及治疗1周后HAMD评分、HAMA评分及HAMD睡眠因子评分差异无统计学意义（P〉0．05），治疗2周、4周、8周后，观察组各项目评分低于对照组，差异有统计学意义（P〈0．05）；2组治疗1周、2周、4周、8周的HAMD、HAMA减分率差异有统计学意义，且观察组减分率大于对照组，差异有统计学意义（P〈0．05）。结论：舍曲林联合小剂量喹硫平在治疗抑郁症患者焦虑失眠症状中的效果优于单用舍曲林，治疗效果明显，值得借鉴。

Objective： Analysis of low- dose quetiapine combined clinical efficacy of sertraline in patients with anxiety, depression, insomnia, and provide reference for clinical diagnosis and treatment. Methods： Our hospital will comply with ICD - 10 depressive episode or recurrent depression diagnostic criteria as the observed object 160 patients were randomly divided into sertraline joint quetiapine group and sertraline alone group, 80 cases in each group. Comparing two groups of patients one week, two weeks, four weeks, eight weeks of the Hamilton Depression Scale （HAMD） and Hamilton Anxiety Scale （HAMA） and HAMD sleep factor case. Results： Two groups of pa- tients before treatment and after treatment one week HAMD score, HAMA and HAMD score sleep factor scores showed no significant difference （P 〉 0.05 ）, the treatment of two weeks, four weeks, eight weeks later, observed each item score than the control group group, the difference was statistically significant （ P 〈 0.05 ） ; treatment, one week, two weeks, four weeks, eight weeks of HAMD, HA- MA reduction rate difference was statistically significant, and the reduction rate of the observation group than the control group, the differ- ence was statistically significant （P 〈 0.05）. Conclusion： Sertraline in combination with low - dose quetiapine in the treatment of de- pression in patients with anxiety and insomnia better than sertraline alone treatment effect is obvious, it is worth learning from.